November 19, 2019
New FOURIER Analysis Evaluates Benefit of Repatha for Recent MI
November 19, 2019—Amgen announced a new analysis from the FOURIER study, demonstrating a benefit of Repatha (evolocumab) in patients who experienced a recent myocardial infarction (MI). The company advised that the results were presented at AHA 2019, the American Heart Association scientific sessions held November 16–18 in Philadelphia, Pennsylvania.
FOURIER is a multinational, phase 3, randomized, double-blind trial designed to evaluate Repatha in combination with statin therapy versus placebo and statin therapy in reducing cardiovascular (CV) events.
In the new analysis of the FOURIER outcomes study, 5,711 patients who experienced an MI within 1 to 12 months of randomization were compared with 16,609 patients with a more distant MI (> 12 months before randomization). The goal was to assess the efficacy of Repatha on the primary endpoint (time to CV death, MI, stroke, unstable angina, coronary revascularization) and the key secondary endpoint (time to CV death, MI, stroke).
According to Amgen, the risk reduction for MI, stroke, or CV death was 25% in Repatha-treated patients treated within 1 year post-MI, compared with 15% in Repatha-treated patients with a more distant MI.
Robert Giugliano, MD, commented, “These results demonstrate the importance of intensive lipid-lowering therapy in the first year following a heart attack and provide additional evidence that evolocumab significantly reduces CV risk and improves outcomes for high-risk patients.” Dr. Giugliano is a Senior Investigator at the TIMI Study Group at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.